For research and education only · Not reviewed by a medical professional · Disclaimer

← PepsRadar home

EXPLORE THE BIOLOGY

Peptides for Heart & Circulation: What the Human Evidence Shows

Content updated · how dates work

Vascular tone, critical-care physiology, and clinical anticoagulation.

This topic groups related research questions. Shared biology does not make different peptides interchangeable, or establish a clinical benefit. Compare each paper’s population, preparation, and measured outcome.

Circulation & clotting: what the human evidence shows

Each peptide is sorted by the strongest kind of human study among its profile’s selected studies, and the row shows what that study found and who was studied. A higher tier means stronger evidence exists, not that the peptide works for circulation & clotting: the best trial may be small, negative or about a different condition. No doses.

PeptideStrongest human evidence in our sourcesFDAHuman safety data
FDA-approved medicine (4)Approved for the specific uses on its label, which may not be this goal.
BivalirudinVALIDATE-SWEDEHEART STEMI subgroup (2021) · Human randomized trial (prespecified subgroup)
The composite of death, myocardial infarction, or major bleeding occurred in 12.5% versus 13.0%: hazard ratio 0.95 (95% CI 0.78–1.17).
Limitation: The composite comparison was not statistically significant. Access route, accompanying antiplatelet treatment, and subgroup context limit generalization to every procedure.
Studied: 3,005 patients with ST-elevation myocardial infarction in a prespecified VALIDATE-SWEDEHEART subgroup.
FDA-approvedFDA label
EnlicitideCORALreef Lipids: enlicitide versus placebo for 52 weeks (2026) · Human randomized phase 3 trial
LDL cholesterol fell by about 57% with enlicitide and rose by 3% with placebo at week 24, a difference of about 56 percentage points. Reductions held at week 52, and non-HDL cholesterol, apolipoprotein B and lipoprotein(a) also fell more than with placebo. An earlier phase 2b trial reported reductions of up to about 61% after eight weeks.
Limitation: The trial measured cholesterol levels, not heart attacks, strokes or deaths. Whether enlicitide lowers those events, as the injected PCSK9 antibodies have been shown to, is being tested in a separate outcomes trial that had not reported when this page was checked.
Studied: 2,909 adults who had already had a major atherosclerotic event, or were at risk of a first one, with LDL cholesterol above set thresholds…
FDA-approvedFDA label
TerlipressinCONFIRM (2021) · Human randomized trial
Verified hepatorenal-syndrome reversal occurred in 32% versus 17%. At 90 days, deaths occurred in 51% versus 45%; respiratory-disorder deaths occurred in 11% versus 2%.
Limitation: Improvement in the specified kidney-function endpoint did not demonstrate a survival advantage. Serious respiratory harms are essential context for the result.
Studied: 300 adults with type 1 hepatorenal syndrome, randomized 199 to terlipressin and 101 to placebo.
FDA-approvedFDA label
VasopressinVASST (2008) · Human randomized trial
Mortality at 28 days was 35.4% versus 39.3% (P=0.26). At 90 days it was 43.9% versus 49.6% (P=0.11). Neither overall comparison was statistically significant.
Limitation: An apparent subgroup difference in less severe shock does not establish overall mortality superiority. Critical-care treatment context limits application to other populations.
Studied: 778 patients with septic shock who were already receiving vasopressors.
FDA-approvedFDA label
Randomized human trials (2)At least one randomized or placebo-controlled trial, which may be small, negative or about another condition.
PACAP-38PACAP-38 challenge after eptinezumab or placebo (2025) · Human randomized provocation study
Migraine occurred in 10 of 19 versus 12 of 19 participants; the difference was not significant (P=0.74). Headache was common after the challenge.
Limitation: The small provocation study does not establish therapeutic benefit of PACAP-38 or a definitive clinical prevention strategy.
Studied: 38 participants with migraine without aura, 19 in each pretreatment group.
Not approvedTrials only
VIPTESICO aviptadil trial (2023) · Human randomized trial
The primary outcome was not significantly better with aviptadil: odds ratio 1.11, 95% CI 0.80–1.55, P=0.54. Mortality was also not significantly different.
Limitation: This negative comparison should remain visible. It neither proves benefit nor answers every proposed chronic use of VIP.
Studied: 461 people with COVID-19-associated respiratory failure.
Not approvedTrials only
Animal and lab studies only (1)No human study in our sources.
B7-33See the profile for the animal and lab research.Not approvedNone

Selected studies, not a systematic review. Approval belongs to a specific product and use. Compare two side by side on the comparison pages.

FEATURED GUIDE

Antibody, peptide or gene silencer: three ways to block PCSK9 and lower LDLRepatha, Praluent, Leqvio and the new pill enlicitide all lower LDL cholesterol by targeting the same protein, PCSK9. They are very different kinds of molecules, and only some have been shown to prevent heart attacks and strokes.

B7-33

B7-33 is a short, lab-designed peptide built from part of relaxin-2, a natural hormone best known for its role in pregnancy. It was designed to keep relaxin's anti-scarring and blood-vessel effects in a smaller molecule. Its evidence comes from animal and cell studies, not people.

Research topics

Read the studies →

Bivalirudin

Bivalirudin is a direct thrombin-inhibitor peptide used in procedural anticoagulation. The featured analysis examined patients with ST-elevation myocardial infarction undergoing coronary intervention.

Prescription medicines

Read the studies →

Enlicitide

Enlicitide is a ring-shaped peptide designed to block PCSK9, the same target as the antibody medicines Repatha and Praluent, but taken as a daily pill instead of an injection. The FDA approved it in July 2026 under the brand name Lipfendra to lower LDL cholesterol in adults with high cholesterol.

Prescription medicines

Read the studies →

PACAP-38

PACAP-38 is a signaling peptide used in migraine-provocation research. The selected clinical study tested whether prior CGRP-pathway treatment prevented a migraine response to a PACAP-38 challenge.

Research topics

Read the studies →

Terlipressin

Terlipressin is a vasopressin-related medicine used in a specific hepatorenal-syndrome setting. Its kidney-function results must be considered with the risk of serious respiratory complications.

Prescription medicines

Read the studies →

Vasopressin

Arginine vasopressin is a nine-residue hormone involved in water balance and vascular tone. VASST compared vasopressin with norepinephrine in septic shock.

Prescription medicines

Read the studies →

VIP

Vasoactive intestinal peptide participates in vascular and immune signaling. A large trial of intravenous aviptadil in COVID-19 respiratory failure did not show a significant improvement in its primary outcome.

Research topics

Read the studies →

See something wrong on this page? Report a mistake · Corrections

FREE PEPSRADAR ACCOUNT

We check sellers’ lab reports with the testing labs themselves.

So far 89 of the 105 lab reports we looked up matched the testing lab’s own record, and 12 did not.

A free account shows which sellers, report by report, plus daily prices, deals, Ask PepsRadar and alerts. If you want it, the PepsRadar Weekly brings new research and FDA news once a week. No dosing advice.

Create a free accountWhat members get →